Evidence map›Paper›PMID 23878065›Full record

ArticleThe Journal of pathology2013

Identification of a recurrent transforming UBR5-ZNF423 fusion gene in EBV-associated nasopharyngeal carcinoma.

Grace Ty Chung, Raymond Wm Lung, Angela By Hui, Kevin Yl Yip, John Ks Woo, Chit Chow, Carol Yk Tong, Sau-Dan Lee, Jessie Wf Yuen, Samantha Wm Lun and 11 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Future of Radiotherapy in Nasopharyngeal Carcinoma.The British journal of radiology · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. TheClinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 5 countries.

Grace Ty ChungDepartment of Anatomical and Cellular Pathology, State Key Laboratory in Oncology in South China, Prince of Wales Hospital, The Chinese University of Hong Kong, SAR; Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, SAR.
Raymond Wm Lung
Angela By Hui
Kevin Yl Yip
John Ks Woo
Chit Chow
Carol Yk Tong
Sau-Dan Lee
Jessie Wf Yuen
Samantha Wm Lun
Ken Ky Tso
Nathalie Wong
Sai-Wah Tsao
Timothy Tc Yip
Pierre Busson
Hyungtae Kim
Jeong-Sun Seo
Brian O'Sullivan
Fei-Fei Liu
Ka-Fai To
Kwok-Wai Lo
Chinese University of Hong Kong · HKOntario Institute for Cancer Research · CAMacrogen (South Korea) · KRPrince of Wales Hospital · CNInstitut de Recherche Dupuy de Lôme · FRQueen Elizabeth Hospital · CNUniversity of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is a distinct type of head and neck cancer which is prevalent in southern China, south-east Asia and northern Africa. The development and stepwise progression of NPC involves accumulation of multiple gross genetic changes during the clonal expansion of Epstein-Barr virus (EBV)-infected nasopharyngeal epithelial cell population. Here, using paired-end whole-transcriptome sequencing, we discovered a number of chimeric fusion transcripts in a panel of EBV-positive tumour lines. Among these transcripts, a novel fusion of ubiquitin protein ligase E3 component n-recognin 5 (UBR5) on 8q22.3 and zinc finger protein 423 (ZNF423) on 16q12.1, identified from the NPC cell line C666-1, was recurrently detected in 12/144 (8.3%) of primary tumours. The fusion gene contains exon 1 of UBR5 and exons 7-9 of ZNF423 and produces a 94 amino acid chimeric protein including the original C-terminal EBF binding domain (ZF29-30) of ZNF423. Notably, the growth of NPC cells with UBR5-ZNF423 rearrangement is dependent on expression of this fusion protein. Knock-down of UBR5-ZNF423 by fusion-specific siRNA significantly inhibited the cell proliferation and colony-forming ability of C666-1 cells. The transforming ability of UBR5-ZNF423 fusion was also confirmed in NIH3T3 fibroblasts. Constitutive expression of UBR5-ZNF423 in NIH3T3 fibroblasts significantly enhanced its anchorage-independent growth in soft agar and induced tumour formation in a nude mouse model. These findings suggest that expression of UBR5-ZNF423 protein might contribute to the transformation of a subset of NPCs, possibly by altering the activity of EBFs (early B cell factors). Identification of the oncogenic UBR5-ZNF423 provides new potential opportunities for therapeutic intervention in NPC.

Indexed as

Amino Acid SequenceAnimalsBlotting, WesternCarcinomaCell Line, TumorDNA-Binding ProteinsEpstein-Barr Virus InfectionsFemaleHumansIn Situ Hybridization, FluorescenceMaleMiceMice, NudeMiddle AgedMolecular Sequence DataNasopharyngeal CarcinomaDNA-Binding Proteinsornithine decarboxylase antizymeProteinsRecombinant Fusion ProteinsRNA, Small InterferingUbiquitin-Protein LigasesUBR5 protein, humanEpstein-Barr virusgene rearrangementnasopharyngeal carcinomaoncogenetranscriptome sequencingUBR5-ZNF423 fusion

Identifiers

PMID23878065
PMCPMC4166696
OpenAlexW1598545767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.